Loading...
•
Jun 30
Eli Lilly Q2 2025 Earnings Report
Eli Lilly delivered strong Q2 2025 performance driven by product volume growth and margin expansion.
Key Takeaways
Lilly reported 38% year-over-year revenue growth to $15.56 billion and a 92% increase in EPS to $6.29, driven by robust sales of Zepbound and Mounjaro, expanded margins, and raised full-year guidance.
Worldwide revenue grew 38% to $15.56 billion
Volume increased 42%, offsetting a 6% price decline
Gross margin expanded to 84.3% of revenue
Full-year revenue and EPS guidance were raised
Eli Lilly
Eli Lilly
Eli Lilly Revenue by Segment
Eli Lilly Revenue by Geographic Location
Revenue by Segment
Mounjaro Revenue
CapyFin.comZepbound Revenue
CapyFin.comVerzenio Revenue
CapyFin.comRevenue by Geographic Location
U.S. Market Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Lilly raised its full-year 2025 financial outlook across revenue, EPS, and margins based on strong first half performance.
Positive Outlook
- Full-year revenue guidance increased to $60.0–62.0 billion
- Reported EPS guidance raised to $20.85–22.10
- Non-GAAP EPS guidance raised to $21.75–23.00
- Reported performance margin guidance increased to 42.0–43.5%
- Non-GAAP performance margin guidance increased to 43.0–44.5%
Challenges Ahead
- Reported other income/(expense) expected at a $750–650 million expense
- Non-GAAP other income/(expense) expected at a $700–600 million expense
- Reported effective tax rate guidance increased to approx. 19%
- Guidance excludes acquired IPR&D charges after Q2 2025
- Does not reflect potential future policy or tariff changes
Revenue & Expenses
Visualization of income flow from segment revenue to net income